ClinicalTrials.Veeva

Menu

Fiberoptic Bronchoscopy and Bronchoalveolar Lavage in Critically Ill Ventilated Patients

F

Free University of Brussels (ULB)

Status

Unknown

Conditions

Respiratory Disease
Bronchoalveolar Lavage (BAL)
Fiberoptic Bronchoscopy (FOB)

Treatments

Procedure: Bronchoalveolar Lavage (BAL)
Diagnostic Test: Electrical Impedance Tomography (EIT)
Diagnostic Test: Arterial Blood Gas test (ABG)
Procedure: Fiberoptic Bronchoscopy (FOB)

Study type

Observational

Funder types

Other

Identifiers

NCT04502368
SRB2020-289
P2020/375 (Other Identifier)

Details and patient eligibility

About

Fiberoptic bronchoscopy (FOB) is widely used as a diagnostic or therapeutic procedure in intensive care units. Patients with ARDS or COVID-19 disease often undergoes to these procedures. However, intensive care patients might suffer from serious side effects such as prolonged oxygen desaturation and adverse change in lung compliance and resistance. This study aims to evaluate these changes and determine their impact on patient stability.

Full description

Fiberoptic bronchoscopy (FOB) is widely used in intensive care units as a diagnostic or therapeutic procedure. FOB in respiratory failure patients supported by mechanical ventilation may worsen hypoxemia and hypercapnia, therefore FOB requires careful consideration in this patient population. The generally accepted indications for FOB in ventilated patients are removal of retained secretions, resolution of atelectasis and evaluation of hemoptysis. A diagnostic indication is the bronchoalveolar lavage (BAL), to sample the lower respiratory tract without contamination. Studies of FOB performed in mechanically ventilated patients suggest an acceptable safety profile, except for the occurrence of hypoxemia as the main adverse event. Bronchoalveolar Lavage (BAL) in normal volunteers is reported to be safe and does not lead to measurable changes in pulmonary function parameters. However, in intensive care patients may suffer from serious side effects such as prolonged oxygen desaturation. Moreover, reductions in arterial oxygen tension (PaO2) have been reported to persist in some patients for 4 h and more after the procedure. Authors reported the BAL procedure is associated to a worsening of PaO2/FiO2 ratio, in several ARDS patients the drop in PaO2 was higher than 30%. Moreover a physiological study in patients undergoing FOB and BAL showed adverse change in lung compliance and resistance.

The purpose of this prospective study is to determine the alterations in respiratory mechanics (regional compliance and resistance) and gas exchange induced by FOB and BAL up to 6 hours after the procedure. The lung regional ventilation evaluation will be made by electrical impedance tomography (EIT).

Enrollment

15 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Mechanically ventilated ICU patients requiring a FOB or FOB + BAL

Exclusion criteria

  • PaO2/FiO2 ratio <100
  • Age < 18 years
  • Pregnancy
  • Unstable angina and recent (less than 1 week) myocardial infarction
  • Uncontrolled cranial hypertension
  • Major hemodynamic instability
  • Any previous lung surgery (except for lung transplantation)
  • Obesity (BMI > 50)
  • Chest circumference > 150 cm
  • Electronic implanted device (pacemaker, neurostimulator, etc.)

Patients who had undergone several bronchoscopy procedures could not be included twice.

Trial contacts and locations

1

Loading...

Central trial contact

Francesco Ricottilli, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems